机构：[a]Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital,Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education,Fudan University, Shanghai, China[b]Department of Pathology, the Eastern Hepatobiliary SurgeryHospital, Second Military Medical University, Shanghai, China[c]Department of InterventionalRadiology, Zhongshan Hospital, Fudan University, Shanghai, China[d]Department of Radiology,Zhongshan Hospital, Fudan University, Shanghai, China[e]Department of Hepatic Surgery, the EasternHepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China[f]Institute ofHepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China[g]Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin,China[h]Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China四川大学华西医院[i]Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, FourthMilitary Medical University, Xi’an, China[j]Department of Interventional Radiology, Chinese PLAGeneral Hospital, Beijing, China[k]Department of Interventional Radiology, the Tumor Hospital ofHarbin Medical University, Harbin, China[l]Department of Interventional Oncology, GuangdongGeneral Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China[m]Departmentof Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China[n]Departmentof Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China[o]Department ofInterventional Ultrasound, Chinese PLA General Hospital, Beijing, China[p]Department of Radiology,Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China广东省人民医院[q]Editorial Department of Chinese Journal of Digestive Surgery, Chongqing, China[r]Department ofRadiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai,China[s]Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China[t]Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China[u]Department ofintegrated treatment, Tumor Hospital of Fudan University, Shanghai, China[v]Department of Hepatobiliary and Spleenary Surgery, the Affiliated Shengjing Hospital, ChinaMedical University, Shenyang, China中国医科大学附属盛京医院[w]Department of Hepatic Surgery, Affiliated Provincial Hospital,Anhui Medical University, Hefei, China[x]Department of Nuclear Medicine, the First Hospital ofChina Medical University, Shenyang, China[y]Department of Radiation Oncology, National CancerCenter/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing, China[z]Department of Oncology, Peking University International Hospital, Beijing, China[A]Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China[B]Departmentof General Surgery, the First Hospital of Jilin University, Jilin, China[C]Department of Liver Surgery,Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences,Beijing, China[D]Department of Interventional Radiology, the First Affiliated Hospital of XinjiangMedical University, Urumqi, China[E]Department of Nuclear Medicine, Zhongshan Hospital, FudanUniversity, Shanghai, China[F]Department of Liver Surgery, West China Hospital of Sichuan University,Chengdu, China四川大学华西医院[G]Department of Hepato-Pancreato-Biliary Surgery, Peking University CancerHospital and Institute, Beijing, China[H]Department of Gastrointestinal Oncology, Affiliated HospitalCancer Center, Academy of Military Medical Sciences, Beijing, China[I]Department of InterventionalOncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第一医院[J]Departmentof Hepatic Surgery and Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, SecondMilitary Medical University, Shanghai, China[K]Department of Hepatobiliary Surgery, ZhongshanHospital of Xiamen University, Xiamen, China[L]Department of Hepatobiliary and PancreaticSurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[M]Department ofHepatobiliary Surgery, Peking University People’s Hospital, Beijing, China[N]Department of Radiology,Zhongda Hospital, Medical School, Southeast University, Nanjing, China[O]Department of AbdominalSurgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union MedicalCollege, Beijing, China[P]Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital,School of Medicine, Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[Q]Department of Hepatobiliary andPancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, TsinghuaUniversity, Beijing, China[R]Department of Hepatobiliary Surgery, Tianjin Medical University CancerInstitute and Hospital, Tianjin, China[S]Department of Medical Oncology, PLA Cancer Center, NanjingBayi Hospital, Nanjing, China[*a]Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University 180 Fenglin Road, Shanghai 200032 (China)[*b]Department of Medical Oncology, PLA Cancer Center Nanjing Bayi Hospital Nanjing 210002 (China)
Background: Hepatocellular carcinoma (HCC) (about 85-90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people. Summary: This guideline presents official recommendations of the National Health and Family Planning Commission of the People's Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China. The guideline was written by more than 50 experts in the field of HCC in China (including liver surgeons, medical oncologists, hepatologists, interventional radiologists, and diagnostic radiologists) on the basis of recent evidence and expert opinions, balance of benefits and harms, cost-benefit strategies, and other clinical considerations. Key Messages: The guideline presents the Chinese staging system, and recommendations regarding patients with HCC in China to ensure optimum patient outcomes. (C) 2018 S. Karger AG, Basel
第一作者机构：[a]Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital,Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education,Fudan University, Shanghai, China
通讯机构：[*a]Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University 180 Fenglin Road, Shanghai 200032 (China)[*b]Department of Medical Oncology, PLA Cancer Center Nanjing Bayi Hospital Nanjing 210002 (China)
推荐引用方式(GB/T 7714)：
Jian Zhou,Hui-Chuan Sun,Zheng Wang,et al.Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)[J].LIVER CANCER.2018,7(3):235-260.doi:10.1159/000488035.
APA：
Jian Zhou,Hui-Chuan Sun,Zheng Wang,Wen-Ming Cong,Jian-Hua Wang...&Jia Fan.(2018).Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).LIVER CANCER,7,(3)
MLA：
Jian Zhou,et al."Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)".LIVER CANCER 7..3(2018):235-260
